https://www.fortunebusinessinsights.com/antibiotics-market-104583

Antibiotics Market Insights 2032: Growth in
Generic vs Branded Antibiotic Share
The antibiotics market plays a vital role in global healthcare by offering effective treatment options for a
wide range of bacterial infections. This market continues to expand due to increasing cases of infectious
diseases, rising awareness about antibiotic therapies, and advancements in drug development. With growing
demand from both developed and developing nations, especially across hospitals and outpatient settings,
the market has seen steady innovation in formulations, combinations, and delivery mechanisms. However,
challenges such as antibiotic resistance and regulatory hurdles remain key concerns. Continued investment
in R&D, coupled with government initiatives for antimicrobial stewardship, is expected to support long-term
market growth.
According to Fortune Business Insights, the global antibiotics market size was valued at USD 41.63 billion
in 2024. The market is projected to grow from USD 43.17 billion in 2025 to USD 58.24 billion by
2032, exhibiting a CAGR of 4.4% during the forecast period. North America dominated the antibiotics
market with a market share of 45.14% in 2024.
Top Companies in the Market
 Pfizer Inc. (U.S.)
 Abbott (U.S.)
 GSK plc. (U.K.)
 Sandoz Group AG (Switzerland)
 Bayer AG (Germany)
 Bristol-Myers Squibb Company (U.S.)
 Merck & Co., Inc. (U.S.)
 Astellas Pharma Inc. (Japan)

Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.) (U.S.)
 AbbVie Inc. (U.S.)
Key Industry Development
In October 2024, Iterum Therapeutics plc. (Ireland) received FDA approval for ORLYNVAH (sulopenem
etzadroxil with probenecid), targeting uncomplicated urinary tract infections (uUTIs). This novel approval
reflects increasing attention on specialized antibiotic therapies.
Market Drivers & Restraints